Figure 6.

Nar suppresses the growth of MCF-7/TR xenograft tumors

(A) TEM image of Nar-LP nanoparticles. (B and C) The cytotoxicity of Nar-LP and Nar in MCF-7 cells and MCF-7/TR cells was determined using the CCK-8 assay. (D) Schematic plan for the administration of Nar-LP and Nar. (E) Representative image of MCF-7/TR xenograft tumors after treatment. Nar (2 mg/kg) was administered daily via intraperitoneal injection, and Nar-LP (5 mg/kg) was administered daily via tail vein injection. (F) Measurement of tumor volume at indicated time points after different treatments. (G) Weights of xenografted tumors were summarized. (H) The body weights of nude mice in each group during the treatment. (I and J) Total proteins were extracted from excised tumors, and the expression levels of STAT3, p-STAT3, and cyclin D1were determined by western blot. (K and L) The IHC staining analyzed Ki67, STAT3, and p-STAT3 in MCF-7/TR xenograft tumors. Data are shown as mean ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.